Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth M Steinberg

Showing results (451-460 of 481) with videos related to

Pageof 49
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2020
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell TrialNirali N Shah, Steven L Highfill, Haneen Shalabi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2022
Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology GroupDavid Milewski, Hyun Jung, G Thomas Brown, et al.
BJU International|January 19, 2016
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancerRavi A Madan, Fatima H Karzai, Yang-Min Ning, et al.
Blood|February 22, 2013
Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantationDaniel H Fowler, Miriam E Mossoba, Seth M Steinberg, et al.
Journal for Immunotherapy of Cancer|December 6, 2018
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutationsFatima Karzai, David VanderWeele, Ravi A Madan, et al.
Cancer Cell|May 30, 2017
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS LymphomaMichail S Lionakis, Kieron Dunleavy, Mark Roschewski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2023
Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain MetastasesSarah Jenkins, Wei Zhang, Seth M Steinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2020
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt LymphomaMark Roschewski, Kieron Dunleavy, Jeremy S Abramson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2015
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian CancerShivaani Kummar, Amit M Oza, Gini F Fleming, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2021
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALLRegina M Myers, Agne Taraseviciute, Seth M Steinberg, et al.
Pageof 49

Showing results (451-460 of 481) with videos related to

Sort By:
Pageof 49
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2020
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell TrialNirali N Shah, Steven L Highfill, Haneen Shalabi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2022
Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology GroupDavid Milewski, Hyun Jung, G Thomas Brown, et al.
BJU International|January 19, 2016
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancerRavi A Madan, Fatima H Karzai, Yang-Min Ning, et al.
Blood|February 22, 2013
Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantationDaniel H Fowler, Miriam E Mossoba, Seth M Steinberg, et al.
Journal for Immunotherapy of Cancer|December 6, 2018
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutationsFatima Karzai, David VanderWeele, Ravi A Madan, et al.
Cancer Cell|May 30, 2017
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS LymphomaMichail S Lionakis, Kieron Dunleavy, Mark Roschewski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2023
Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain MetastasesSarah Jenkins, Wei Zhang, Seth M Steinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2020
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt LymphomaMark Roschewski, Kieron Dunleavy, Jeremy S Abramson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2015
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian CancerShivaani Kummar, Amit M Oza, Gini F Fleming, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2021
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALLRegina M Myers, Agne Taraseviciute, Seth M Steinberg, et al.
Pageof 49